1. Home
  2. ZCMD vs IMRN Comparison

ZCMD vs IMRN Comparison

Compare ZCMD & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zhongchao Inc.

ZCMD

Zhongchao Inc.

HOLD

Current Price

$1.84

Market Cap

6.9M

Sector

Real Estate

ML Signal

HOLD

Logo Immuron Limited

IMRN

Immuron Limited

N/A

Current Price

$0.70

Market Cap

6.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ZCMD
IMRN
Founded
2012
1994
Country
China
Australia
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.9M
6.8M
IPO Year
2019
2016

Fundamental Metrics

Financial Performance
Metric
ZCMD
IMRN
Price
$1.84
$0.70
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
51.5K
21.6K
Earning Date
04-28-2026
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.18
$0.68
52 Week High
$1.95
$2.38

Technical Indicators

Market Signals
Indicator
ZCMD
IMRN
Relative Strength Index (RSI) 71.62 38.89
Support Level $1.02 $0.69
Resistance Level $1.93 $0.89
Average True Range (ATR) 0.19 0.06
MACD -0.02 -0.01
Stochastic Oscillator 79.23 0.00

Price Performance

Historical Comparison
ZCMD
IMRN

About ZCMD Zhongchao Inc.

ZHONGCHAO Inc is an offshore holding company incorporated in the Cayman Islands. Through its subsidiaries, it is a platform-based internet technology company offering services to patients with oncology and other diseases in China. It provide the healthcare information, education, and training services to the healthcare professionals under their MDMOOC brand. It also provide focused patient management services, through Zhongxun IT system and WeChat mini program and Zhongxin Health WeChat mini program, to pharmaceutical enterprises and NFP customers.

About IMRN Immuron Limited

Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.

Share on Social Networks: